Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
Inventors
Jung, Hoe Yune • Jeon, Jong Su • Kim, Bo Bae • LEE, Heon Jong • Song, Moon Ki • LEE, Do Hyun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11607441-B2
Publication Date
2023-03-21
Expiration Date
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating diabetes, comprising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharmaceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensitizer, a sodium-glucose co-transporter (a sodium-glucose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 inhibitor).
Core Innovation
The invention relates to a diabetes-preventing or treating pharmaceutical composition and method that include zinc salt and cyclo-hispro (Cyclo-Z), together with an antidiabetic drug. The zinc salt and cyclo-hispro (or pharmaceutically acceptable salt thereof) are administered in a defined weight ratio with the selected antidiabetic drug.
In the disclosed combinations, the antidiabetic drug is selected from insulin sensitizers, sodium-glucose co-transporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors. The zinc salt and cyclo-hispro (Cyclo-Z) are administered simultaneously, separately or sequentially with the antidiabetic drug, and defined weight-ratio constraints are provided for pairing with each selected drug class.
The disclosed combinations are stated to produce a synergistic effect on glucose absorption, blood glucose regulation, and/or inhibition of glycated hemoglobin. The partial disclosure also states that reduced side effects are achieved compared with antidiabetic drugs alone.
Claims Coverage
The document provides one independent claim directed to a method for treating diabetes using a zinc salt plus cyclo-hispro (Cyclo-Z) in a specified weight ratio with a selected antidiabetic drug, with administration timing options. The claim includes three sets of weight-ratio constraints tied respectively to insulin sensitizers, sodium-glucose co-transporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors (refined by dependent claims).
Treating diabetes with zinc salt and cyclo-hispro in a defined weight ratio
A method for treating diabetes in a subject, comprising administering a zinc salt and cyclo-hispro (or a pharmaceutically acceptable salt thereof) at a weight ratio of the zinc salt to the cyclo-hispro (or its pharmaceutically acceptable salt) of from 2:1 to 3:1.
Combination with an antidiabetic drug from specific classes
Administering, with the zinc salt and cyclo-hispro combination, an antidiabetic drug selected from insulin sensitizers, sodium-glucose co-transporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors.
Administration timing and class-specific weight-ratio constraints
Administering the zinc salt and cyclo-hispro (or its pharmaceutically acceptable salt) simultaneously, separately or sequentially with the antidiabetic drug, and specifying class-specific weight-ratio constraints for insulin sensitizers, sodium-glucose co-transporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors.
Overall, the claim coverage focuses on combining zinc salt with cyclo-hispro (Cyclo-Z) at a defined internal weight ratio and pairing that combination with specific antidiabetic drug classes using additional defined weight-ratio constraints, with flexible simultaneous, separate, or sequential administration.
Stated Advantages
Produces a synergistic effect on glucose absorption, blood glucose regulation, and/or inhibition of glycated hemoglobin.
Provides reduced side effects versus antidiabetic drugs alone.
Documented Applications
Treating diabetes by administering a zinc salt and cyclo-hispro (Cyclo-Z) together with an antidiabetic drug selected from insulin sensitizers, sodium-glucose co-transporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors.
Interested in licensing this patent?